As the Hong Kong market navigates a period of mixed economic signals and cautious investor sentiment, it remains crucial to identify companies with strong growth potential and significant insider ownership. In this article, we will explore three SEHK-listed growth companies that have demonstrated up to 32% revenue growth, showcasing why high insider ownership can be an indicator of robust future performance.
Top 10 Growth Companies With High Insider Ownership In Hong Kong
|
Name |
Insider Ownership |
Earnings Growth |
|
Laopu Gold (SEHK:6181) |
36.4% |
34.7% |
|
Akeso (SEHK:9926) |
20.5% |
55.0% |
|
Pacific Textiles Holdings (SEHK:1382) |
11.2% |
37.7% |
|
Fenbi (SEHK:2469) |
31.2% |
22.4% |
|
Zylox-Tonbridge Medical Technology (SEHK:2190) |
18.7% |
69.8% |
|
Zhejiang Leapmotor Technology (SEHK:9863) |
15% |
76.4% |
|
Adicon Holdings (SEHK:9860) |
22.4% |
35.8% |
|
DPC Dash (SEHK:1405) |
38.2% |
104.2% |
|
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) |
13.9% |
109.2% |
|
Beijing Airdoc Technology (SEHK:2251) |
28.6% |
93.4% |
Here’s a peek at a few of the choices from the screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: BYD Company Limited, along with its subsidiaries, operates in the automobiles and batteries sectors across the People’s Republic of China, Hong Kong, Macau, Taiwan, and internationally with a market cap of approximately HK$753.26 billion.
Operations: BYD’s revenue segments include CN¥507.52 billion from automobiles and related products, and CN¥154.49 billion from mobile handset components, assembly services, and other products.
Insider Ownership: 30.1%
Revenue Growth Forecast: 13.8% p.a.
BYD, a growth company with high insider ownership in Hong Kong, has shown robust financial performance and strategic expansion. Earnings grew by 36.2% over the past year, and revenue is forecast to grow faster than the Hong Kong market at 13.8% per year. Recent earnings reported for H1 2024 include sales of CNY 294.77 billion and net income of CNY 13.63 billion. Additionally, BYD’s strategic partnership with Uber aims to deploy 100,000 electric vehicles globally, further solidifying its market position.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Meituan operates as a technology retail company in the People’s Republic of China with a market cap of HK$724.88 billion.
Operations: The company’s revenue segments are comprised of CN¥228.13 billion from Core Local Commerce and CN¥77.56 billion from New Initiatives.
Insider Ownership: 11.3%
Revenue Growth Forecast: 12.9% p.a.
Meituan’s earnings are forecast to grow significantly at 25.8% per year, outpacing the Hong Kong market. Recent earnings for H1 2024 showed robust growth with sales reaching CNY 155.53 billion and net income doubling to CNY 16.72 billion from the previous year. The company has also announced a share repurchase program worth $1 billion, indicating strong confidence from its board in future prospects despite low forecasted return on equity (18.4%).
Simply Wall St Growth Rating: ★★★★★★
Overview: Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs with a market cap of HK$42.30 billion.
Operations: The company generates revenue primarily from the research, development, production, and sale of biopharmaceutical products amounting to CN¥1.87 billion.
Insider Ownership: 20.5%
Revenue Growth Forecast: 32.5% p.a.
Akeso’s revenue is forecast to grow 32.5% annually, significantly outpacing the Hong Kong market. While recent earnings showed a decline with H1 2024 revenue at CNY 1.02 billion and a net loss of CNY 238.59 million, the company is expected to become profitable in three years. Trading at a substantial discount to its fair value, Akeso has high insider ownership and strong growth prospects driven by innovative drug developments like ivonescimab and AK117.
Key Takeaways
Ready For A Different Approach?
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include SEHK:1211 SEHK:3690 and SEHK:9926.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com